Evidence map›Paper›PMID 23902773›Full record

ArticleThe Journal of biological chemistry2013

A monoclonal antibody (MCPR3-7) interfering with the activity of proteinase 3 by an allosteric mechanism.

Lisa C Hinkofer, Susanne A I Seidel, Brice Korkmaz, Francisco Silva, Amber M Hummel, Dieter Braun, Dieter E Jenne, Ulrich Specks

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Inhibitory antibodies identify unique sites of therapeutic vulnerability in rhinovirus and other enteroviruses.Proceedings of the National Academy of Sciences of the United States of America · 2020
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 4 countries.

Lisa C HinkoferFrom the Comprehensive Pneumology Center, Institute of Lung Biology and Disease (iLBD), University Hospital, Ludwig Maximilians University and Helmholtz Zentrum München, Member of the German Center for Lung Research (DZL), Max-Lebsche-Platz 31, 81377 Munich, Germany.
Susanne A I Seidel
Brice Korkmaz
Francisco Silva
Amber M Hummel
Dieter Braun
Dieter E Jenne
Ulrich Specks
Ludwig-Maximilians-Universität München · DEMayo Clinic · USMax Planck Society · DEPontificia Universidad Católica de Chile · CL

Funding

VASCULITIS CLINICAL RESEARCH NETWORK (VCRN): RARE DISEASEU54RR019497 · NCRR · BOSTON UNIVERSITY MEDICAL CAMPUS · PI MERKEL, PETER A · 2003 to 2008
$6.1M
PR3-ANCA Subsets and Disease PhenotypeR01AR049806 · NIAMS · MAYO CLINIC COLL OF MEDICINE, ROCHESTER · PI SPECKS, ULRICH · 2002 to 2005
$1.0M
IDENTIFICATION AND VALIDATION OF BIOMARKERS FOR VASCULITISRC1AR058303 · NIAMS · BOSTON UNIVERSITY MEDICAL CAMPUS · PI MERKEL, PETER A, MONACH, PAUL A · 2009 to 2010
$1.0M
NCRR NIH HHS U54 RR019497NCRR NIH HHS U54-RR019497NIAMS NIH HHS R01 AR049806NIAMS NIH HHS R01-AR49806NIAMS NIH HHS RC1 AR058303NIAMS NIH HHS RC1-AR58303
6 · The paper itself

Abstract

Proteinase 3 (PR3) is an abundant serine protease of neutrophil granules and a major target of autoantibodies (PR3 anti-neutrophil cytoplasmic antibodies) in granulomatosis with polyangiitis. Some of the PR3 synthesized by promyelocytes in the bone marrow escapes the targeting to granules and occurs on the plasma membrane of naive and primed neutrophils. This membrane-associated PR3 antigen may represent pro-PR3, mature PR3, or both forms. To discriminate between mature PR3 and its inactive zymogen, which have different conformations, we generated and identified a monoclonal antibody called MCPR3-7. It bound much better to pro-PR3 than to mature PR3. This monoclonal antibody greatly reduced the catalytic activity of mature PR3 toward extended peptide substrates. Using diverse techniques and multiple recombinant PR3 variants, we characterized its binding properties and found that MCPR3-7 preferentially bound to the so-called activation domain of the zymogen and changed the conformation of mature PR3, resulting in impaired catalysis and inactivation by α1-proteinase inhibitor (α1-antitrypsin). Noncovalent as well as covalent complexation between PR3 and α1-proteinase inhibitor was delayed in the presence of MCPR3-7, but cleavage of certain thioester and paranitroanilide substrates with small residues in the P1 position was not inhibited. We conclude that MCPR3-7 reduces PR3 activity by an allosteric mechanism affecting the S1' pocket and further prime side interactions with substrates. In addition, MCPR3-7 prevents binding of PR3 to cellular membranes. Inhibitory antibodies targeting the activation domain of PR3 could be exploited as highly selective inhibitors of PR3, scavengers, and clearers of the PR3 autoantigen in granulomatosis with polyangiitis.

Indexed as

Allosteric SiteAnimalsAntibodies, Antineutrophil CytoplasmicAntibodies, MonoclonalAutoimmunityCatalysisFluorescence Resonance Energy TransferHEK293 CellsHumansMiceMice, Inbred BALB CMyeloblastinNeutrophil ActivationNeutrophilsProtein ConformationRecombinant ProteinsAntibodies, Antineutrophil CytoplasmicAntibodies, MonoclonalMyeloblastinRecombinant ProteinsAllosteryAntibodiesAutoimmunityNeutrophilProteaseProtease InhibitorProteinase 3ThermophoresisZymogenα1-Proteinase Inhibitor

Identifiers

PMID23902773
PMCPMC3772210
OpenAlexW1999482985

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.